The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line gemcitabine versus treatment of physician’s choice in patients with metastatic and stage IV breast cancer: A prospective cohort study.
Kazutaka Narui
No relevant relationships to disclose
Takashi Ishikawa
No relevant relationships to disclose
Kazuhiro Shimada
No relevant relationships to disclose
Kumiko Kida
No relevant relationships to disclose
Daisuke Shimizu
No relevant relationships to disclose
Ikuko Ota
No relevant relationships to disclose
Kounosuke Kiuchi
No relevant relationships to disclose
Mikiko Tanabe
No relevant relationships to disclose
Mari Saito Oba
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Sadatoshi Sugae
No relevant relationships to disclose
Takako Doi
No relevant relationships to disclose
Satoshi Hasegawa
No relevant relationships to disclose
Tomoyuki Morita
No relevant relationships to disclose
Ayako Kito
No relevant relationships to disclose
Takashi Chishima
No relevant relationships to disclose
Yasushi Ichikawa
No relevant relationships to disclose
Itaru Endo
No relevant relationships to disclose